Patent and regulatory hurdles combined with low returns on investment are stifling antibiotic R&D in the pharmaceutical industry.
References
Bad bugs, no drugs: as antibiotic R&D stagnates... a public health crisis brews (Infectious Diseases Society of America, Alexandria, Virginia, 2004).
Utility Examination Guidelines, 66 Fed. Reg. 1092 http://www.uspto.gov/web/officer/com/sol/notices/utilexmguide.pdf (2001).
Tufts Center for the Study of Drug Development pegs cost of a new prescription medicine at $802 million. http://csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=6 (2001).
Fermini, B. & Fossa, A.A. Nat. Rev. Drug Discov. 2, 439–447 (2003).
Harris, G. Approval of antibiotic worried safety officials. New York Times (19 July 2006).
FDA rejects Replidyne drug application. Denver Business Journal (23 October 2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Katz, M., Mueller, L., Polyakov, M. et al. Where have all the antibiotic patents gone?. Nat Biotechnol 24, 1529–1531 (2006). https://doi.org/10.1038/nbt1206-1529
Issue Date:
DOI: https://doi.org/10.1038/nbt1206-1529
- Springer Nature America, Inc.
This article is cited by
-
Reported antibiotic use among patients in the multicenter ANDEMIA infectious diseases surveillance study in sub-saharan Africa
Antimicrobial Resistance & Infection Control (2024)
-
Mitigation of acyl-homoserine lactone (AHL) based bacterial quorum sensing, virulence functions, and biofilm formation by yttrium oxide core/shell nanospheres: Novel approach to combat drug resistance
Scientific Reports (2019)
-
Production of macrolide antibiotics from a cytotoxic soil Streptomyces sp. strain ZDB
World Journal of Microbiology and Biotechnology (2017)
-
Antimicrobial and cytotoxic evaluation of eugenol derivatives
Medicinal Chemistry Research (2016)
-
A new antibiotic with potent activity targets MscL
The Journal of Antibiotics (2015)